TEVA
FDA Chlorthalidone dissolution testing recall: More than 25,000 bottles of blood pressure medication recalled. Check which tablets are impacted?
Blood Pressure tablets FDA chlorthalidone dissolution testing recall: Chlorthalidone medication is prescribed to keep the blood pressure in check. The pills generally decrease the water and salt in the body through uptick in urine flow.
Asian Games India schedule: Check full list of events, date, venue and other key details
Asian Games: Indian athletes face new challenges in 2026, with the Asian Games as a key event. The 2025 season saw mixed results across various sports for the nation. Archery and boxing showed promise, while athletics experienced disappointment. The Aichi-Nagoya Asian Games offer a chance to build momentum for future competitions. This multi-sport event is crucial for athletes heading towards the Olympics.
Sun Pharma gets ratings boost from Moody's, S&P over USD 11.75-bn Organon & Co acquisition bid
Rating agencies Moody's and S&P assigned investment-grade ratings to Sun Pharmaceutical Industries. This action follows Sun Pharma's proposed acquisition of US-based Organon & Co. The deal is expected to significantly bolster Sun Pharma's business position and revenue base. Organon will contribute substantially to the group's earnings after the acquisition. This strategic move will enhance Sun Pharma's scale and geographic reach.
Sun Pharma among 9 pharmaceutical firms to lower drug prices for Americans, Trump says
Nine pharmaceutical firms reached deals with the Trump administration for lower drug prices. These agreements expand the total number of companies to twenty-six manufacturers. The deals cover medicines for chronic and rare diseases, benefiting Medicaid programs. Sun Pharma will contribute antibiotics to the US Strategic Active Pharmaceutical Ingredients Reserve. These initiatives aim to reduce reliance on foreign suppliers and lower costs.
Teva shows the flip side of rapidly growing corporate leverage
Teva slashed its earnings goals for a second time this year and cut its dividend, too.
Teva appoints Dipankar Bhattacharjee as Prez, CEO Global Generic Group
As President and CEO of Teva Generics Europe, Bhattacharjee has a proven track record of improving revenues and profitability, significantly increasing operating profit margins in the European generics business, Teva said.
DRL, Cipla, Aurobindo among others to buy products from Teva
The remedy requires Teva to divest the drug portfolio to 11 firms and marks the largest drug divestiture order in an FTC pharmaceutical merger case.
Dr. Reddy’s buys eight ANDAs from Teva for $350 million
Dr. Reddy’s said the acquisition of ANDAs is contingent on closing of the Teva generics transaction and approval by the US Federal Trade Commission.
Israel's Teva buys Allergan generic drug company for $40.5 billion
Teva Pharmaceutical Industries Ltd. says it is purchasing Dublin-based Allergan PLC's generic pharmaceuticals business for $40.5 billion.
Mylan rejects Teva's $40 billion merger offer as undervalued
Drug major Mylan has rejected a $40 billion unsolicited merger offer from Israel's Teva Pharmaceutical Industries calling the bid undervalued.
Teva offers to buy Mylan for $40.1 billion
Teva, the world’s biggest maker of generic medicines, offered $82 a share in cash and stock for Mylan, according to a statement.
Venus Remedies ties up with Israel's Teva for anti-cancer drug
Chandigarh based Pharma major has entered into agreement with Israel-based generic drug maker Teva to sell anti- cancer drug in Canadian market.
Teva settles patent dispute with Orchid Pharma
Teva has settled patent dispute with Orchid Chemicals & Pharma pertaining to Parkinson’s disease drug Azilect (rasagiline mesylate) in the US market.
Teva Pharma, P&G sets up OTC plant in Gujarat
Israel-based Teva Pharmaceuticals, an $18 billion generic drug maker will set up OTC medicine facility in Gujarat in collaboration with Procter & Gamble.
Natco Pharma loses patent case against Teva Pharmaceutical Industries of anti-sclerosis drug
Natco Pharma has lost a patent litigation against Israel's Teva Pharmaceutical Industries in the US over multiple sclerosis treatment drug, Copaxone.
Jeremy Levin named as next CEO of Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Ltd named Jeremy Levin of Bristol-Myers Squibb Coto to replace Shlomo Yanai as chief executive officer.
Ranbaxy Laboratories falls on payment concerns to Teva Pharmaceuticals, delay in settlment with FDA
Ranbaxy's share price fell 1.66% due to concerns about payment to Teva Pharmaceuticals and delay in settlement with US authorities.
Teva to buy Taiyo stake for $460 million, bid for rest
Teva Pharmaceutical Industries Ltd agreed to buy 57% of Taiyo Pharmaceutical Industry Co Ltd. for $460 million and bid for the rest.
Zydus drags Teva to court for antitrust violations
Zydus Cadila, an Ahmedabad-based pharmaceutical company, has taken Teva Pharmaceuticals, the world’s largest generic drug maker, to court in the US seeking damages for Teva’s antitrust violations and unfair trade practices.
Load More
